A month has gone by since the last earnings report for Aflac (AFL) . Shares have lost about 5.5% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Aflac due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Aflac Incorporated before we dive into how investors and analysts have reacted as of la ...

Aflac Incorporated (AFL) is an insurance company that provides supplemental financial‑protection products to individuals and groups, mainly in the U.S. and Japan. Its operations focus on helping people cover costs when major medical or life‑insurance benefits fall short. The company’s headquarters are in Columbus, Georgia. It has a market capitalization of $58.06 billion, making it a “large-cap” stock. Aflac’s shares reached a 52-week high of $119.32 on Feb. 5, but are down 5.7% from that level. The mark ...

Aflac Incorporated (NYSE:AFL) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. Wells Fargo Raises Aflac (AFL) Target, Revises Earnings Outlook and Valuation Approach On February 25, Wells Fargo analyst Elyse Greenspan raised the firm’s price recommendation on Aflac Incorporated (NYSE:AFL) to $118 from $109. Itreiterated an Equal Weight rating on the shares. The firm said that after reviewing fourth-quarter guidance across the sector, it is lowering EPS estimates for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-07434 Aflac Incorporated (Exact name of registrant as specified in its charter) | Georgia | | 58-1167100 | | | --- | --- | --- | --- ...

Core Viewpoint - Aflac is addressing Japan's demographic challenges through innovation in products and market strategies, focusing on growth while maintaining expense discipline and profitability [1][3]. Financial Performance - Aflac returned nearly $4.8 billion to shareholders in 2025, including $3.5 billion in share repurchases, marking a record year and extending its dividend increase streak to 43 consecutive years [2][4]. - The company is targeting an internal capital marker near 10%, currently at approximately 6% [4][17]. Market Dynamics - In the U.S., brokers account for about 80% of the market and generated over 60% of Aflac's U.S. sales in 2025, contributing to a 14% growth in overall group products [5][13]. - Aflac is experiencing sales momentum in Japan, particularly with products aimed at younger customers, and is expanding its distribution through banks and agencies [6][11]. Product Innovation - Key products driving growth include Tsumitasu, Miraito, and Anshin Palette, with Tsumitasu designed to adjust rates as interest rates change, providing a competitive edge [9][10][12]. - The company is leveraging AI to enhance agent efficiency and streamline enrollment processes, particularly in Japan [14]. Strategic Focus - Aflac remains committed to organic growth and does not pursue M&A unless it aligns with operational and strategic goals, emphasizing a focus on supplemental health products [18]. - The company sees significant underpenetrated opportunities in the U.S. market, particularly in dental and vision insurance, and plans to increase advertising to communicate product value [19].

Core Insights - Aflac is experiencing positive growth in both the Japanese and U.S. insurance markets, with a focus on innovative products to meet changing consumer needs [2][3] Group 1: Japanese Market - Aflac has successfully introduced new products such as Tsumitasu and Miraito, focusing on cancer insurance to align with the aging population's needs [2] - The company is committed to reinventing its offerings in Japan to drive sales growth [2] Group 2: U.S. Market - Aflac reports a 3% overall increase in its U.S. market, with group products showing tremendous growth that outpaces the market [3] - The company is placing greater emphasis on its traditional business to enhance performance in the U.S. [3]

Aflac 2026 Conference Call Summary Company Overview - **Company**: Aflac Inc. (NYSE: AFL) - **Date**: February 11, 2026 - **Key Speakers**: Virgil Miller (President), David Young (SVP of Capital Markets) Key Points Industry and Market Position - Aflac operates in two of the largest insurance markets globally: Japan and the U.S. [2][3] - The company is a pioneer in the Third Sector market, particularly in cancer insurance, and continues to dominate this segment in Japan [5][6] Japan Market Insights - **Sales Growth**: Aflac has focused on innovative products to align sales growth with the aging population in Japan. The introduction of the Tsumitasu product and the cancer insurance product Miraito has led to solid growth [2][3][5] - **Target Audience**: Aflac is targeting younger consumers with products designed to be flexible and appealing, allowing existing customers to purchase additional benefits [6][7] - **Distribution Strategy**: Aflac has strengthened its distribution through bank alliances and agency forces, increasing the number of banks offering Aflac products [9][10][21] - **Product Flexibility**: The Tsumitasu product allows for rate adjustments as interest rates change, providing a competitive edge in the market [9][16] U.S. Market Insights - **Competitive Environment**: The U.S. market is highly competitive, with an increasing number of companies offering supplemental and voluntary benefits. Aflac has seen a 16% increase in the conversion rate of new agents [25][26][27] - **Sales Performance**: Aflac reported $1.6 billion in sales for the previous year, marking one of the highest sales years on record. Group products grew by 14%, significantly outpacing the market [40][28] - **Product Suite**: Aflac remains a leader in cancer insurance and supplemental health products. The company is focused on streamlining the enrollment process to enhance agent efficiency [30][31] Financial Performance - **Capital Management**: Aflac returned nearly $4.8 billion to shareholders through dividends and share repurchases, maintaining a record of 43 consecutive years of dividend increases [4][42] - **Excess Capital**: The company has significant excess capital and is focused on organic growth, with a strategy to evaluate potential M&A opportunities if gaps are identified [42][44][54] Future Outlook - **Growth Opportunities**: Aflac plans to focus on expanding its dental and vision products and enhancing its life absence and disability offerings. The company aims to leverage its strong brand reputation to drive growth in the U.S. market [61][62] - **Technological Advancements**: Aflac is utilizing AI to improve efficiency in Japan, with plans to enhance the enrollment process and customer interactions in the U.S. [35][36] Additional Insights - **Medical Inflation**: Rising medical costs and high deductibles are driving demand for supplemental insurance, which Aflac is leveraging in its sales strategy [39][41] - **Brand Recognition**: Aflac's strong brand presence in Japan and the U.S. is a key asset, with efforts to maintain consumer trust and awareness through marketing initiatives [58][61] This summary encapsulates the key insights and strategic directions discussed during the Aflac 2026 conference call, highlighting the company's performance, market strategies, and future growth opportunities.

Core Insights - Aflac Incorporated is a leading provider of supplemental health and life insurance, primarily operating in the U.S. and Japan, with a market cap of $59.5 billion [1] - The company's stock has underperformed compared to the broader market, gaining 9.5% over the past 52 weeks, while the S&P 500 Index increased by 12.2% [1] - Year-to-date, Aflac's stock is up 6.5%, contrasting with a slight decline in the S&P 500 [1] - Aflac has outperformed the SPDR S&P Insurance ETF, which saw a 1.8% increase over the past 52 weeks [2] Financial Performance - In Q4 2025, Aflac reported total revenue of $4.9 billion, a decline of 9.3% year-over-year [4] - Adjusted earnings decreased by 5.4% to $818 million, while adjusted EPS rose slightly to $1.57 [4] - Net investment gains fell by 46.3% year-over-year to $537 million, down from $1 billion [4] - Shareholders' equity increased to $29.5 billion, or $56.85 per share, up from $26.1 billion a year earlier, with a strong annualized return on equity of 19% [4] Analyst Expectations - For the current fiscal year ending in December, analysts project Aflac's EPS to decline by 1.7% year-over-year to $7.36 [5] - The consensus rating among 16 analysts is a "Hold," with two "Strong Buy," one "Moderate Buy," nine "Hold," and four "Strong Sell" ratings [5] Market Outlook - Barclays has lowered its price target for Aflac to $101 from $104, maintaining an "Equal-Weight" rating [6] - The firm expresses cautious optimism regarding life insurers, citing strong capital positions and solid cash flow as positives, while noting challenges such as spread compression and rising technology spending [6]

Key Takeaways AFL reported Q4 adjusted EPS of $1.57, up 0.6% year over year, but missing consensus estimates.AFL revenues fell 9.9% to $4.9B as net investment income dropped and operating expenses rose.AFL saw Japan premium sales jump 15.7%, while U.S. earnings declined on higher benefits and expenses.Aflac Incorporated (AFL) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.57, which missed the Zacks Consensus Estimate by 8.2%. The bottom line improved 0.6% year over year. Adjusted reven ...

Aflac (NYSE:AFL) Q4 2025 Earnings call February 05, 2026 08:00 AM ET Company ParticipantsAlex Scott - CFABradley Dyslin - Global Chief Investment Officer and President, Aflac Global InvestmentsDaniel Amos - Chairman and CEODavid Young - Head of Investor RelationsJack Matten - CFAKoichiro Yoshizumi - Head of Marketing and Sales DivisionMax Brodén - CFOVirgil Miller - PresidentNone - TranslatorConference Call ParticipantsJoel Hurwitz - AnalystJohn Barnidge - Managing Director and Senior Research AnalystSuneet ...